Pharma & Biotech

Longeveron Inc. (NASDAQ: LGVN) is approaching a series of decisive milestones, with 2026 shaping up to be a potentially transformative...

The focus for Remsleep and its investors is undergoing a significant shift. With the regulatory groundwork now firmly established for...

Shares of Electrocore are currently trading in a quiet phase, with broader macroeconomic concerns over inflation and global trade dominating...

The clinical-stage biotech firm Ensysce Biosciences has entered what many consider the most pivotal period in its development timeline. With...

For investors in Nexalin Technology, the focus has shifted from daily stock price movements to the company's underlying clinical progression....

The biotechnology firm Genprex finds itself at a critical inflection point. Investor attention is sharply divided between promising advancements in...

The biotech firm Scinai is navigating a critical strategic transition. To secure its position within a highly competitive sector, the...

The planned acquisition of RAPT Therapeutics by pharmaceutical giant GSK is entering its final stages. As the deal progresses toward...

Investors in Organon & Co. breathed a collective sigh of relief last week. An independent review found no evidence of...

The investment narrative surrounding Iovance Biotherapeutics is shifting. The company has reached a pivotal juncture, moving beyond pure research into...